Events

Drug-like antibodies by design and directed evolution

Free Food,
Lecture / Panel
 
For NYU Community

Peter Tessier

Speaker:

Peter M. Tessier
Departments of Chemical Engineering, Pharmaceutical Sciences and Biomedical Engineering, Biointerfaces Institute, University of Michigan

Abstract:

The biotech industry has seen an explosion in the development of therapeutic antibodies in the last decade, and today most of the best-selling drugs are monoclonal antibodies. The advantages of antibodies as therapeutics – namely their high affinity, specificity, potency, stability, manufacturability and low toxicity – are compelling. Nevertheless, there are many fundamental challenges associated with antibody discovery and development that require key technical advances in order to improve the rational generation of potent antibody therapeutics. I will discuss our progress in addressing some of these challenges, including the design, evolution, selection and characterization of drug-like antibodies with high affinity, specificity, stability and solubility.

  • 10:30 Refreshments
  • 10:45–12:00 Talk